Search for other papers by T P McVeigh in
Google Scholar
PubMed
Search for other papers by R J Mulligan in
Google Scholar
PubMed
Search for other papers by U M McVeigh in
Google Scholar
PubMed
Search for other papers by P W Owens in
Google Scholar
PubMed
Search for other papers by N Miller in
Google Scholar
PubMed
Search for other papers by M Bell in
Google Scholar
PubMed
Aix-Marseille Université, Faculté de Médecine, Marseille, France
Search for other papers by F Sebag in
Google Scholar
PubMed
Aix-Marseille Université, Faculté de Médecine, Marseille, France
Search for other papers by C Guerin in
Google Scholar
PubMed
Search for other papers by D S Quill in
Google Scholar
PubMed
Search for other papers by J B Weidhaas in
Google Scholar
PubMed
Search for other papers by M J Kerin in
Google Scholar
PubMed
Search for other papers by A J Lowery in
Google Scholar
PubMed
Introduction
MicroRNAs (miRNAs) are small noncoding RNA molecules that exert post-transcriptional effects on gene expression by binding with cis-regulatory regions in target messenger RNA (mRNA). Polymorphisms in genes encoding miRNAs or in miRNA–mRNA binding sites confer deleterious epigenetic effects on cancer risk. miR-146a has a role in inflammation and may have a role as a tumour suppressor. The polymorphism rs2910164 in the MIR146A gene encoding pre-miR-146a has been implicated in several inflammatory pathologies, including cancers of the breast and thyroid, although evidence for the associations has been conflicting in different populations. We aimed to further investigate the association of this variant with these two cancers in an Irish cohort.
Methods
The study group comprised patients with breast cancer (BC), patients with differentiated thyroid cancer (DTC) and unaffected controls. Germline DNA was extracted from blood or from saliva collected using the DNA Genotek Oragene 575 collection kit, using crystallisation precipitation, and genotyped using TaqMan-based PCR. Data were analysed using SPSS, v22.
Results
The total study group included 1516 participants. This comprised 1386 Irish participants; 724 unaffected individuals (controls), 523 patients with breast cancer (BC), 136 patients with differentiated thyroid cancer (DTC) and three patients with dual primary breast and thyroid cancer. An additional cohort of 130 patients with DTC from the South of France was also genotyped for the variant. The variant was detected with a minor allele frequency (MAF) of 0.19 in controls, 0.22 in BC and 0.27 and 0.26 in DTC cases from Ireland and France, respectively. The variant was not significantly associated with BC (per allele odds ratio = 1.20 (0.98–1.46), P = 0.07), but was associated with DTC in Irish patients (per allele OR = 1.59 (1.18–2.14), P = 0.002).
Conclusion
The rs2910164 variant in MIR146A is significantly associated with DTC, but is not significantly associated with BC in this cohort.
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Shruti Khare in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Kranti Khadilkar in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Background
Bilateral adrenal masses may have aetiologies like hyperplasia and infiltrative lesions, besides tumours. Hyperplastic and infiltrative lesions may have coexisting hypocortisolism. Bilateral tumours are likely to have hereditary/syndromic associations. The data on clinical profile of bilateral adrenal masses are limited.
Aims
To analyse clinical, biochemical and radiological features, and management outcomes in patients with bilateral adrenal masses.
Methods
Retrospective analysis of 70 patients with bilateral adrenal masses presenting to a single tertiary care endocrine centre from western India (2002–2015).
Results
The most common aetiology was pheochromocytoma (40%), followed by tuberculosis (27.1%), primary adrenal lymphoma (PAL) (10%), metastases (5.7%), non-functioning adenomas (4.3%), primary bilateral macronodular adrenal hyperplasia (4.3%), and others (8.6%). Age at presentation was less in patients with pheochromocytoma (33 years) and tuberculosis (41 years) compared with PAL (48 years) and metastases (61 years) (P<0.001). The presenting symptoms for pheochromocytoma were hyperadrenergic spells (54%) and abdominal pain (29%), whereas tuberculosis presented with adrenal insufficiency (AI) (95%). The presenting symptoms for PAL were AI (57%) and abdominal pain (43%), whereas all cases of metastasis had abdominal pain. Mean size of adrenal masses was the largest in lymphoma (5.5cm) followed by pheochromocytoma (4.8cm), metastasis (4cm) and tuberculosis (2.1cm) (P<0.001). Biochemically, most patients with pheochromocytoma (92.8%) had catecholamine excess. Hypocortisolism was common in tuberculosis (100%) and PAL (71.4%) and absent with metastases (P<0.001).
Conclusion
In evaluation of bilateral adrenal masses, age at presentation, presenting symptoms, lesion size, and biochemical features are helpful in delineating varied underlying aetiologies.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Jes Sloth Mathiesen in
Google Scholar
PubMed
Search for other papers by Jens Peter Kroustrup in
Google Scholar
PubMed
Steno Diabetes Center North Jutland, Aalborg, Denmark
Search for other papers by Peter Vestergaard in
Google Scholar
PubMed
Search for other papers by Per Løgstrup Poulsen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Sten Schytte in
Google Scholar
PubMed
Search for other papers by Stefano Christian Londero in
Google Scholar
PubMed
Search for other papers by Henrik Baymler Pedersen in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
Search for other papers by Jens Bentzen in
Google Scholar
PubMed
Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark
Search for other papers by Sören Möller in
Google Scholar
PubMed
Search for other papers by Mette Gaustadnes in
Google Scholar
PubMed
Search for other papers by Maria Rossing in
Google Scholar
PubMed
Search for other papers by Finn Cilius Nielsen in
Google Scholar
PubMed
Search for other papers by Kim Brixen in
Google Scholar
PubMed
Search for other papers by Christian Godballe in
Google Scholar
PubMed
Search for other papers by Danish Thyroid Cancer Group (DATHYRCA) in
Google Scholar
PubMed
A recent study proposed new TNM groupings for better survival discrimination among stage groups for medullary thyroid carcinoma (MTC) and validated these groupings in a population-based cohort in the United States. However, it is unknown how well the groupings perform in populations outside the United States. Consequently, we conducted the first population-based study aiming to evaluate if the recently proposed TNM groupings provide better survival discrimination than the current American Joint Committee on Cancer (AJCC) TNM staging system (seventh and eighth edition) in a nationwide MTC cohort outside the United States. This retrospective cohort study included 191 patients identified from the nationwide Danish MTC cohort between 1997 and 2014. In multivariate analysis, hazard ratios for overall survival under the current AJCC TNM staging system vs the proposed TNM groupings with stage I as reference were 1.32 (95% CI: 0.38–4.57) vs 3.04 (95% CI: 1.38–6.67) for stage II, 2.06 (95% CI: 0.45–9.39) vs 3.59 (95% CI: 1.61–8.03) for stage III and 5.87 (95% CI: 2.02–17.01) vs 59.26 (20.53–171.02) for stage IV. The newly proposed TNM groupings appear to provide better survival discrimination in the nationwide Danish MTC cohort than the current AJCC TNM staging. Adaption of the proposed TNM groupings by the current AJCC TNM staging system may potentially improve accurateness in survival discrimination. However, before such an adaption further population-based studies securing external validity are needed.
Search for other papers by Nassim Ghaffari-Tabrizi-Wizsy in
Google Scholar
PubMed
Search for other papers by Christina Angelika Passegger in
Google Scholar
PubMed
Search for other papers by Laura Nebel in
Google Scholar
PubMed
Search for other papers by Fabian Krismer in
Google Scholar
PubMed
Search for other papers by Gudrun Herzer-Schneidhofer in
Google Scholar
PubMed
Search for other papers by Gert Schwach in
Google Scholar
PubMed
Search for other papers by Roswitha Pfragner in
Google Scholar
PubMed
Preclinical trials of medullary thyroid cancer (MTC) therapeutics require both in vitro and in vivo analyses. Human tumour xenografted rodent models, which are considered the ‘gold standard’ to study and validate the efficacy and toxicity of lead compounds before translation to clinical trials, are very expensive, subject to organismal variability and ethical controversies. The avian chorioallantoic membrane (CAM) assay provides an alternative versatile, cost-effective and ethically less objectionable short-term, in vivo model for reliable screening of drugs. In this work, we grafted two MTC cell lines and patient-derived MTC tumour samples onto the avian CAM and characterised the resulted tumours histologically and immunohistochemically. Our findings provide the evidence that the CAM assay is a suitable model for studying the pathophysiology of MTC and can even be used as in vivo system for drug testing.
Department of Medicine IV, Medical Center – University of Freiburg
Search for other papers by Roland Därr in
Google Scholar
PubMed
Search for other papers by Jonas Kater in
Google Scholar
PubMed
Search for other papers by Peggy Sekula in
Google Scholar
PubMed
Search for other papers by Birke Bausch in
Google Scholar
PubMed
Search for other papers by Tobias Krauss in
Google Scholar
PubMed
Search for other papers by Christoph Bode in
Google Scholar
PubMed
Search for other papers by Gerd Walz in
Google Scholar
PubMed
Search for other papers by Hartmut P Neumann in
Google Scholar
PubMed
Search for other papers by Stefan Zschiedrich in
Google Scholar
PubMed
The optimal treatment strategy for patients with small non-functioning VHL-related incidentalomas is unclear. We searched the Freiburg VHL registry for patients with radiologic evidence of pheochromocytoma/paraganglioma (PHEO/PGL). In total, 176 patients with single, multiple, and recurrent tumours were identified (1.84 tumours/patient, range 1–8). Mean age at diagnosis was 32 ± 16 years. Seventy-four percent of tumours were localised to the adrenals. Mean tumour diameter was 2.42 ± 2.27 cm, 46% were <1.5 cm. 24% of tumours were biochemically inactive. Inactive tumours were significantly smaller than active PHEO/PGL at diagnosis (4.16 ± 2.80 cm vs 1.43 ± 0.45 cm; P < 0.025) and before surgery (4.89 ± 3.47 cm vs 1.36 ± 0.43 cm; P < 0.02). Disease was stable in 67% of 21 patients with evaluable tumours ≤1.5 cm according to RECIST and progressed in 7. Time till surgery in these patients was 29.5 ± 20.0 months. A total of 155 patients underwent surgery. PHEO/PGL was histologically excluded in 4 and proven in 151. Of these, one had additional metastatic disease, one harboured another tumour of a different type, and in 2 a second surgery for suspected disease recurrence did not confirm PHEO/PGL. Logistic regression analysis revealed 50% probability for a positive/negative biochemical test result at 1.8 cm tumour diameter. Values of a novel symptom score were positively correlated with tumour size (Rs = 0.46, P < 0.0001) and together with a positive biochemistry a linear size predictor (P < 0.01). Results support standardised clinical assessment and measurement of tumour size and metanephrines in VHL patients with non-functioning incidentalomas <1.5 cm at one year following diagnosis and at individualised intervals thereafter depending on evolving growth dynamics, secretory activity and symptomatology.
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II, Naples, Italy
Search for other papers by Maria Cristina De Martino in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Claudia Pivonello in
Google Scholar
PubMed
Search for other papers by Chiara Simeoli in
Google Scholar
PubMed
Search for other papers by Fortuna Papa in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Adrenocortical carcinomas (ACCs) are rare tumors with scant treatment options for which new treatments are required. The mTOR pathway mediates the intracellular signals of several growth factors, including the insulin-like growth factors (IGFs), and therefore represents a potential attractive pathway for the treatment of several malignancies including ACCs. Several mTOR inhibitors, including sirolimus, temsirolimus and everolimus, have been clinically developed. This review summarizes the results of the studies evaluating the expression of the mTOR pathway components in ACCs, the effects of the mTOR inhibitors alone or in combination with other drugs in preclinical models of ACCs and the early experience with the use of these compounds in the clinical setting. The mTOR pathway seems a potential target for treatment of patients with ACC, but further investigation is still required to define the potential role of mTOR inhibitors alone or in combination with other drugs in the treatment of ACC patients.
Search for other papers by Tiemo S Gerber in
Google Scholar
PubMed
Search for other papers by Arno Schad in
Google Scholar
PubMed
Search for other papers by Nils Hartmann in
Google Scholar
PubMed
Search for other papers by Erik Springer in
Google Scholar
PubMed
Search for other papers by Ulrich Zechner in
Google Scholar
PubMed
Search for other papers by Thomas J Musholt in
Google Scholar
PubMed
Poorly differentiated thyroid carcinoma (PDTC) is a rare malignancy with higher mortality than well-differentiated thyroid carcinoma. The histological diagnosis can be difficult as well as the therapy. Improved diagnosis and new targeted therapies require knowledge of DNA sequence changes in cancer-relevant genes. The TruSeq Amplicon Cancer Panel was used to screen cancer genomes from 25 PDTC patients for somatic single-nucleotide variants in 48 genes known to represent mutational hotspots. A total of 4490 variants were found in 23 tissue samples of PDTC. Ninety-eight percent (4392) of these variants did not meet the inclusion criteria, while 98 potentially pathogenic or pathogenic variants remained after filtering. These variants were distributed over 33 genes and were all present in a heterozygous state. Five tissue samples harboured not a single variant. Predominantly, variants in P53 (43% of tissue samples) were identified, while less frequently, variants in APC, ERBB4, FLT3, KIT, SMAD4 and BRAF (each in 17% of tissue samples) as well as ATM, EGFR and FBXW7 (each in 13% of tissue samples) were observed. This study identified new potential genetic targets for further research in PDTC. Of particular interest are four observed ERBB4 (alias HER4) variants, which have not been connected to this type of thyroid carcinoma so far. In addition, APC and SMAD4 mutations have not been reported in this subtype of cancer either. In contrast to other reports, we did not find CTNNB1 variants.
Search for other papers by Logan Mills in
Google Scholar
PubMed
Search for other papers by Panagiotis Drymousis in
Google Scholar
PubMed
Search for other papers by Yogesh Vashist in
Google Scholar
PubMed
Search for other papers by Christoph Burdelski in
Google Scholar
PubMed
Search for other papers by Andreas Prachalias in
Google Scholar
PubMed
Search for other papers by Parthi Srinivasan in
Google Scholar
PubMed
Search for other papers by Krishna Menon in
Google Scholar
PubMed
Search for other papers by Corina Cotoi in
Google Scholar
PubMed
Search for other papers by Saboor Khan in
Google Scholar
PubMed
Search for other papers by Judith Cave in
Google Scholar
PubMed
Search for other papers by Thomas Armstrong in
Google Scholar
PubMed
Search for other papers by Martin O Weickert in
Google Scholar
PubMed
Search for other papers by Jakob Izbicki in
Google Scholar
PubMed
Search for other papers by Joerg Schrader in
Google Scholar
PubMed
Search for other papers by Andreja Frilling in
Google Scholar
PubMed
Search for other papers by John K Ramage in
Google Scholar
PubMed
Search for other papers by Raj Srirajaskanthan in
Google Scholar
PubMed
Small non-functioning pancreatic NETs (pNETs) ≤2 cm can pose a management dilemma in terms of surveillance or resection. There is evidence to suggest that a surveillance approach can be considered since there are no significant radiological changes observed in lesions during long-term follow-up. However, other studies have suggested loco-regional spread can be present in ≤2 cm pNETs. The aim of this study was to characterise the prevalence of malignant features and identify any useful predictive variables in a surgically resected cohort of pNETs. 418 patients with pNETs were identified from 5 NET centres. Of these 227 were included for main analysis of tumour characteristics. Mean age of patients was 57 years, 47% were female. The median follow-up was 48.2 months. Malignant features were identified in 38% of ≤2 cm pNETs. ROC analysis showed that the current cut-off of 20 mm had a sensitivity of 84% for malignancy. The rate of malignant features is in keeping with other surgical series and challenges the belief that small pNETs have a low malignant potential. This study does not support a 20 mm size cut-off as being a solitary safe parameter to exclude malignancy in pNETs.
Search for other papers by Abdul K Siraj in
Google Scholar
PubMed
Search for other papers by Rong Bu in
Google Scholar
PubMed
Search for other papers by Maham Arshad in
Google Scholar
PubMed
Search for other papers by Kaleem Iqbal in
Google Scholar
PubMed
Search for other papers by Sandeep Kumar Parvathareddy in
Google Scholar
PubMed
Search for other papers by Tariq Masoodi in
Google Scholar
PubMed
Search for other papers by Laila Omar Ghazwani in
Google Scholar
PubMed
Search for other papers by Saif S Al-Sobhi in
Google Scholar
PubMed
Search for other papers by Fouad Al-Dayel in
Google Scholar
PubMed
Search for other papers by Khawla S Al-Kuraya in
Google Scholar
PubMed
Introduction Thyroid cancer is the most frequently occurring endocrine cancer with an increasing incidence rate worldwide and with a frequency among the younger age group ( 1 , 2 ). It is also the second most common malignancy, after breast
Search for other papers by Natalie Rogowski-Lehmann in
Google Scholar
PubMed
Search for other papers by Aikaterini Geroula in
Google Scholar
PubMed
Search for other papers by Aleksander Prejbisz in
Google Scholar
PubMed
Search for other papers by Henri J L M Timmers in
Google Scholar
PubMed
Search for other papers by Felix Megerle in
Google Scholar
PubMed
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Search for other papers by Stephanie M J Fliedner in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Anthony Stell in
Google Scholar
PubMed
Search for other papers by Andrzej Januszewicz in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Background
Pheochromocytomas and paragangliomas (PPGLs) are rare but potentially harmful tumors that can vary in their clinical presentation. Tumors may be found due to signs and symptoms, as part of a hereditary syndrome or following an imaging procedure.
Objective
To investigate potential differences in clinical presentation between PPGLs discovered by imaging (iPPGLs), symptomatic cases (sPPGLs) and those diagnosed during follow-up because of earlier disease/known hereditary mutations (fPPGL).
Design
Prospective study protocol, which has enrolled patients from six European centers with confirmed PPGLs. Data were analyzed from 235 patients (37 iPPGLs, 36 sPPGLs, 27% fPPGLs) and compared for tumor volume, biochemical profile, mutation status, presence of metastases and self-reported symptoms. iPPGL patients were diagnosed at a significantly higher age than fPPGLs (P < 0.001), found to have larger tumors (P = 0.003) and higher metanephrine and normetanephrine levels at diagnosis (P = 0.021). Significantly lower than in sPPGL, there was a relevant number of self-reported symptoms in iPPGL (2.9 vs 4.3 symptoms, P < 0.001). In 16.2% of iPPGL, mutations in susceptibility genes were detected, although this proportion was lower than that in fPPGL (60.9%) and sPPGL (21.5%). Patients with PPGLs detected by imaging were older, have higher tumor volume and more excessive hormonal secretion in comparison to those found as part of a surveillance program. Presence of typical symptoms indicates that in a relevant proportion of those patients, the PPGL diagnosis had been delayed.
Précis
Pheochromocytoma/paraganglioma discovered by imaging are often symptomatic and carry a significant proportion of germline mutations in susceptibility genes.
